Allspring Global Investments
TRDA icon

Allspring Global Investments’s Entrada Therapeutics TRDA Stock Holding History

Allspring Global Investments’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$246K Buy
19,465
+1,970
+11% +$22.6K ﹤0.01% 1570
2025
Q4 		$176K Buy
17,495
+1,560
+10% +$13.1K ﹤0.01% 1588
2025
Q3 		$92.4K Sell
15,935
-157
-1% -$919 ﹤0.01% 1582
2025
Q2 		$108K Sell
16,092
-928
-5% -$7.47K ﹤0.01% 1579
2025
Q1 		$149K Buy
17,020
+5,896
+53% +$73.5K ﹤0.01% 1675
2024
Q4 		$192K Sell
11,124
-9,397
-46% -$170K ﹤0.01% 1677
2024
Q3 		$328K Sell
20,521
-7,110
-26% -$112K ﹤0.01% 1574
2024
Q2 		$394K Buy
27,631
+12,868
+87% +$183K ﹤0.01% 1558
2024
Q1 		$209K Buy
14,763
+11,965
+428% +$169K ﹤0.01% 1697
2023
Q4 		$42.2K Hold
2,798
– – ﹤0.01% 1904
2023
Q3 		$44.2K Buy
+2,798
New +$44.1K ﹤0.01% 2308

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Allspring Global Investments's TRDA Position: Q1 2026 in Review

Allspring Global Investments increased its Entrada Therapeutics (TRDA) stake by 11% in Q1 2026, buying an estimated $22.6K and bringing the position to 19,465 shares worth $246K. The position accounts for ﹤0.01% of the portfolio, ranked #1570.

Allspring Global Investments first reported a position in TRDA in Q3 2023 and has held it in 11 quarters since. The position peaked at $394K in Q2 2024. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Allspring Global Investments held 19,465 shares of Entrada Therapeutics worth $246K as of Q1 2026.
  • Allspring Global Investments bought 1,970 Entrada Therapeutics shares in Q1 2026, an estimated $22.6K.
  • Entrada Therapeutics made up ﹤0.01% of Allspring Global Investments's portfolio in Q1 2026, its #1570 holding.
  • Allspring Global Investments first reported a position in Entrada Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Allspring Global Investments's Entrada Therapeutics position peaked at $394K in Q2 2024.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Allspring Global Investments's 13F filing for Q1 2026, filed 5 May 2026.